GeoVax Expands Gedeptin Cancer Therapy Development to Additional Solid Tumor Types

GeoVax Labs, Inc. has announced the expansion of its oncology development strategy to include assessments of additional solid tumor targets for Gedeptin®, its gene-directed enzyme prodrug therapy. The clinical-stage biotechnology company is working with its oncology advisory team including the Winship Cancer Institute of Emory University to evaluate Gedeptin combinations with immune checkpoint inhibitors in preclinical models of several solid tumor types beyond head and neck cancer.

The company is specifically targeting triple negative breast cancer and cutaneous malignancies in its expanded development efforts. These preclinical models are designed to validate Gedeptin's mechanism of localized intratumoral cytotoxicity that also primes systemic immune responses. The expansion builds on the company's existing Phase 2 clinical trial plans for head and neck squamous cell carcinoma, which will evaluate Gedeptin in combination with pembrolizumab as first-line treatment for patients eligible for curative surgery.

The strategic rationale for this expansion centers on three key factors: checkpoint synergy, therapeutic expansion potential, and timely alignment with recent clinical advancements. Gedeptin's ability to directly debulk tumors while enhancing immune visibility positions it as a potential force multiplier for checkpoint inhibitors. Success in these preclinical programs could support Gedeptin's clinical evaluation into additional solid tumors, addressing what company leadership describes as a critically important area of solid tumor cancer therapy.

The timing of this expansion aligns with recent clinical developments, particularly the KEYNOTE-689 trial results that demonstrated the transformative potential of neoadjuvant checkpoint therapy in head and neck cancer. According to GeoVax Chairman and CEO David A. Dodd, these results provide important context showing how immune-sensitizing strategies like Gedeptin are increasingly vital to maximizing checkpoint efficacy. The company views this expansion as addressing a major value-creation opportunity in cancer therapeutics.

GeoVax's Chief Medical Officer, Dr. Kelly T. McKee, emphasized that the preclinical efforts will provide in-vivo proof of concept for expanding Gedeptin-checkpoint inhibitor combination therapy into additional solid tumor types. This represents a natural evolution of the company's program that positions it at the forefront of immuno-oncology innovation. The company anticipates early readouts from its preclinical modeling work, with results expected to support the design of potential clinical trials in selected solid tumor indications.

In parallel with this expansion effort, GeoVax continues to target initiation of its Phase 2 clinical trial of Gedeptin in combination with Keytruda for head and neck cancer in the second half of 2026. The company is also pursuing potential collaborative discussions regarding both clinical development and potential commercialization of Gedeptin. Gedeptin has already received Orphan Drug Designation for oral and pharyngeal cancers, and its mechanism involves using a non-replicating adenoviral vector to deliver purine nucleoside phosphorylase that converts fludarabine into a cytotoxic compound within the tumor microenvironment.

The expansion of Gedeptin's development represents a significant step in addressing the limitations of current checkpoint monotherapy approaches. By enhancing immune activation within the tumor microenvironment, Gedeptin's tumor-targeting and immune-sensitizing mechanism may help overcome resistance issues that often limit the effectiveness of single-agent immunotherapy. This approach could potentially benefit patients across multiple solid tumor types where current treatment options remain inadequate.